EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Dividend Timetable
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that, further to the passing of the resolution at the AGM, a cash dividend of 1.2p per ordinary share will be paid in relation to its 2021 results as per the below timetable. The dividend will be paid to shareholders, on the register at close of business on 4 November 2022, on 1 December 2022.
The dividend timetable dates are detailed below:
| Ex-dividend date: | 3 November 2022 |
| Record date: | 4 November 2022 |
| Payment date: | 1 December 2022 |
| EKF Diagnostics Holdings plc | |
| Mike Salter, CEO / Marc Davies, CFO | Tel: +44 (0)29 2071 0570 |
| | |
| Singer Capital Markets (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / George Tzimas / Oliver Platts | |
| | |
| Investec Bank plc (Joint Broker) | Tel: +44 (0)20 7597 4000 |
| Gary Clarence / Daniel Adams / Ben Farrow | |
| | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
| Paul McManus / Lianne Applegarth | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
| Point-of-Care | Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
|
| Central Laboratory | Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
|
| Life Sciences | Enzyme fermentation, Custom products and Bulk fermentation
|
| Contract Manufacturing | Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
|
| Laboratory Testing | Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
